We are live on ! Find out more
18.22 USD
-1.06
5.5%
At close Updated Sep 14, 4:00 PM EDT
Pre-market
After hours
18.50
+0.28
1.54%
1 day
-5.5%
5 days
-4.86%
1 month
-30.08%
3 months
-13.16%
6 months
-21.5%
Year to date
-31.27%
1 year
-43.66%
5 years
-77.31%
10 years
-62.25%
 

About: Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.

Employees: 7,802

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 35.3%
Neutral 58.8%
Negative 5.9%
Neutral
The Motley Fool
16 hours ago
Insider at Medical Device Maker Buys More Than 7,500 Shares
The acquisition involved 7,598 shares at a weighted average price of $19.74 per share, representing a total investment of ~$150,000. The transaction size equals 14% of the equity stake held by the executive before the filing.
Insider at Medical Device Maker Buys More Than 7,500 Shares
Positive
Zacks Investment Research
11 days ago
What Makes Enovis (ENOV) a New Buy Stock
Enovis (ENOV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes Enovis (ENOV) a New Buy Stock
Negative
Zacks Investment Research
11 days ago
Enovis (ENOV) Loses 33% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Enovis (ENOV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Enovis (ENOV) Loses 33% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Positive
Zacks Investment Research
12 days ago
Enovis Boosts Surgical Robotics Portfolio With eCential Acquisition
ENOV is set to acquire eCential Robotics to expand into orthopedic surgical robotics, though the deal is expected to pressure 2027 margins.
Enovis Boosts Surgical Robotics Portfolio With eCential Acquisition
Neutral
Seeking Alpha
13 days ago
Enovis Corporation (ENOV) M&A Call Transcript
Enovis Corporation (ENOV) M&A Call Transcript
Enovis Corporation (ENOV) M&A Call Transcript
Positive
MarketBeat
13 days ago
Enovis Targets Robotic Surgery Expansion With €155M eCential Robotics Deal
Enovis NYSE: ENOV said it has entered a binding offer to acquire eCential Robotics, a developer of surgical robotics technology, in a move the orthopedic company said will expand its enabling-technology capabilities and accelerate its pathway into robotic surgery.
Enovis Targets Robotic Surgery Expansion With €155M eCential Robotics Deal
Neutral
PRNewsWire
13 days ago
eCential Robotics Announces Binding Offer from Enovis
eCential Robotics platform to join Enovis' enabling technology portfolio. GRENOBLE, France and FRANKLIN, Tenn.
eCential Robotics Announces Binding Offer from Enovis
Neutral
GlobeNewsWire
13 days ago
Enovis Invests in Innovation with Binding Offer to Acquire eCential Robotics, a Leading Developer of Enabling Technologies and Surgical Robotics
Dallas, TX, Sept. 01, 2026 (GLOBE NEWSWIRE) -- – Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology company, announced today that it has entered into a binding offer to acquire eCential Robotics, a leading developer of enabling technologies and surgical robotics. The acquisition expands the ASTRA™ enabling technology platform with robotic automation capabilities, creating a more comprehensive ecosystem designed to improve surgical precision, streamline workflows, and enhance patient outcomes.
Enovis Invests in Innovation with Binding Offer to Acquire eCential Robotics, a Leading Developer of Enabling Technologies and Surgical Robotics
Neutral
GlobeNewsWire
14 days ago
Enovis to Participate in the 2026 Wells Fargo Healthcare Conference
Dallas, TX, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that it will participate in the 2026 Wells Fargo HealthCare conference on Tuesday, September 8, 2026 at the Encore Boston Harbor.
Enovis to Participate in the 2026 Wells Fargo Healthcare Conference
Positive
Seeking Alpha
24 days ago
Enovis Corporation: Arvis Is Disrupting The Health Care Industry
Enovis Corporation is rated a buy, trading at a 7x EBITDA multiple versus a sector median of 14.7x, with significant upside if Arvis succeeds. Arvis, a zero-footprint, wearable augmented reality device for orthopedic surgery, targets the fast-growing ambulatory surgery center market and recently achieved full commercialization. ENOV's fundamentals are weak—slim margins, high leverage, and thin free cash flow—but these are already priced in, while Arvis's growth potential is not.
Enovis Corporation: Arvis Is Disrupting The Health Care Industry
Price charts implemented using Lightweight Charts™